000075867 001__ 75867
000075867 005__ 20200117213745.0
000075867 0247_ $$2doi$$a10.1093/ofid/ofx258
000075867 0248_ $$2sideral$$a108838
000075867 037__ $$aART-2018-108838
000075867 041__ $$aeng
000075867 100__ $$aBerenguer, J.
000075867 245__ $$aHuman immunodeficiency virus/hepatits C virus coinfection in Spain: Elimination is feasible, but the burden of residual cirrhosis will be significant
000075867 260__ $$c2018
000075867 5060_ $$aAccess copy available to the general public$$fUnrestricted
000075867 5203_ $$aBackground
We assessed the prevalence of antibodies against hepatitis C virus (HCV-Abs) and active HCV infection in patients infected with human immunodeficiency virus (HIV) in Spain in 2016 and compared the results with those of similar studies performed in 2002, 2009, and 2015.
Methods
The study was performed in 43 centers during October-November 2016. The sample was estimated for an accuracy of 2% and selected by proportional allocation and simple random sampling. During 2016, criteria for therapy based on direct-acting antiviral agents (DAA) were at least significant liver fibrosis, severe extrahepatic manifestations of HCV, and high risk of HCV transmissibility.
Results
The reference population and the sample size were 38904 and 1588 patients, respectively. The prevalence of HCV-Abs in 2002, 2009, 2015, and 2016 was 60.8%, 50.2%, 37.7%, and 34.6%, respectively (P trend <.001, from 2002 to 2015). The prevalence of active HCV in 2002, 2009, 2015, and 2016 was 54.0%, 34.0%, 22.1%, and 11.7%, respectively (P trend <.001). The anti-HCV treatment uptake in 2002, 2009, 2015, and 2016 was 23.0%, 48.0%, 59.3%, and 74.7%, respectively (P trend <.001). In 2016, HCV-related cirrhosis was present in 7.6% of all HIV-infected individuals, 15.0% of patients with active HCV, and 31.5% of patients who cleared HCV after anti-HCV therapy.
Conclusions
Our findings suggest that with universal access to DAA-based therapy and continued efforts in prevention and screening, it will be possible to eliminate active HCV among HIV-infected individuals in Spain in the short term. However, the burden of HCV-related cirrhosis will continue to be significant among HIV-infected individuals.
000075867 536__ $$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/RD16-0025-0018$$9info:eu-repo/grantAgreement/ES/ISCIII-FEDER/RD16-0025-0017
000075867 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttp://creativecommons.org/licenses/by-nc-nd/3.0/es/
000075867 590__ $$a3.371$$b2018
000075867 591__ $$aIMMUNOLOGY$$b73 / 157 = 0.465$$c2018$$dQ2$$eT2
000075867 591__ $$aMICROBIOLOGY$$b46 / 133 = 0.346$$c2018$$dQ2$$eT2
000075867 591__ $$aINFECTIOUS DISEASES$$b29 / 89 = 0.326$$c2018$$dQ2$$eT1
000075867 592__ $$a1.48$$b2018
000075867 593__ $$aOncology$$c2018$$dQ1
000075867 593__ $$aNeurology (clinical)$$c2018$$dQ1
000075867 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000075867 700__ $$aJarrín, I.
000075867 700__ $$aPérez-Latorre, L.
000075867 700__ $$aHontañón, V.
000075867 700__ $$aVivancos, M.J.
000075867 700__ $$aNavarro, J.
000075867 700__ $$aTéllez, M.J.
000075867 700__ $$aGuardiola, J.M.
000075867 700__ $$aIribarren, J.A.
000075867 700__ $$aRivero-Juárez, A.
000075867 700__ $$aMárquez, M.
000075867 700__ $$aArtero, A.
000075867 700__ $$aMorano, L.
000075867 700__ $$aSantos, I.
000075867 700__ $$0(orcid)0000-0001-8786-8256$$aMoreno, J.$$uUniversidad de Zaragoza
000075867 700__ $$aFariñas, M.C.
000075867 700__ $$aGalindo, M.J.
000075867 700__ $$aHernando, M.A.
000075867 700__ $$aMontero, M.
000075867 700__ $$aCifuentes, C.
000075867 700__ $$aDomingo, P.
000075867 700__ $$aSanz, J.
000075867 700__ $$aDomíngez, L.
000075867 700__ $$aFerrero, O.L.
000075867 700__ $$aDe La Fuente, B.
000075867 700__ $$aRodríguez, C.
000075867 700__ $$aReus, S.
000075867 700__ $$aHernández-Quero, J.
000075867 700__ $$aGaspar, G.
000075867 700__ $$aPérez-Martínez, L.
000075867 700__ $$aGarcía, C.
000075867 700__ $$aForce, L.
000075867 700__ $$aVeloso, S.
000075867 700__ $$aLosa, J.E.
000075867 700__ $$aVilaró, J.
000075867 700__ $$aBernal, E.
000075867 700__ $$aArponen, S.
000075867 700__ $$aOrtí, A.J.
000075867 700__ $$aChocarro, Á.
000075867 700__ $$aTeira, R.
000075867 700__ $$aAlonso, G.
000075867 700__ $$aSilvariño, R.
000075867 700__ $$aVegas, A.
000075867 700__ $$aGeijo, P.
000075867 700__ $$aBisbe, J.
000075867 700__ $$aEsteban, H.
000075867 700__ $$aGonzález-García, J.
000075867 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000075867 773__ $$g5, 1 (2018), [8 pp]$$pOpen Forum Infectious Diseases$$tOpen Forum Infectious Diseases$$x2328-8957
000075867 8564_ $$s194876$$uhttps://zaguan.unizar.es/record/75867/files/texto_completo.pdf$$yVersión publicada
000075867 8564_ $$s131316$$uhttps://zaguan.unizar.es/record/75867/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000075867 909CO $$ooai:zaguan.unizar.es:75867$$particulos$$pdriver
000075867 951__ $$a2020-01-17-21:29:16
000075867 980__ $$aARTICLE